Alternative Follow-Up Regimen for Methotrexate Treatment.

Area of Science:

• Reproductive Endocrinology
• Pharmacological Treatment of Ectopic Pregnancy
• Clinical Trial Methodology

Background:

• Ectopic pregnancy management often involves methotrexate, requiring serial human chorionic gonadotropin (hCG) monitoring.
• Current standard follow-up is on days 4 and 7 post-methotrexate administration.
• Patient adherence to the day 4 and 7 schedule can be challenging due to logistical difficulties.

Purpose of the Study:

• To compare the efficacy and safety of monitoring hCG levels on post-methotrexate days 5 and 8 versus days 4 and 7.
• To evaluate treatment success rates and need for surgical intervention based on different monitoring schedules.
• To determine if a flexible hCG monitoring schedule impacts ectopic pregnancy management outcomes.

Main Methods:

• Retrospective cohort analysis of patients treated with methotrexate for ectopic pregnancy (2016-2025).
• Comparison of outcomes between patients monitored on days 4 and 7 versus days 5 and 8.
• Data collected included demographics, hCG levels, methotrexate dosage, and need for surgery.
• Treatment success defined as final hCG < 25 mIU/mL; response defined as ≥15% hCG decline.

Main Results:

• No significant differences in patient demographics or baseline characteristics between the two monitoring groups.
• Similar rates of successful methotrexate response (60.0% vs. 63.9%) and overall treatment success (95.2% vs. 83.3%) were observed.
• The majority of successful treatments did not require additional surgical intervention in both cohorts.

Conclusions:

• Monitoring human chorionic gonadotropin (hCG) levels on days 5 and 8 post-methotrexate is a viable alternative to the standard days 4 and 7 schedule.
• This alternative schedule yields similar ectopic pregnancy treatment outcomes.
• The findings support increased flexibility in follow-up timing, potentially improving patient adherence and management convenience.